Validation of the BOADICEA model in a prospective cohort of 
        BRCA1/2 pathogenic variant carriers.

Xin Yang; Thea M Mooij; Goska Leslie; Lorenzo Ficorella; Nadine Andrieu; Karin Kast; Christian F Singer; Anna Jakubowska; Carla H van Gils; Yen Y Tan; Christoph Engel; Muriel A Adank; Christi J van Asperen; Margreet G E M Ausems; Pascaline Berthet; Margriet J Collee; Jackie A Cook; Jacqueline Eason; Karin Y van Spaendonck-Zwarts; D Gareth Evans; Encarna B Gómez García; Helen Hanson; Louise Izatt; Zoe Kemp; Fiona Lalloo; Christine Lasset; Fabienne Lesueur; Hannah Musgrave; Sophie Nambot; Catherine Noguès; Jan C Oosterwijk; Dominique Stoppa-Lyonnet; Marc Tischkowitz; Vishakha Tripathi; Marijke R Wevers; Emily Zhao; Flora E van Leeuwen; Marjanka K Schmidt; Douglas F Easton; Matti A Rookus; Antonis C Antoniou

doi:10.1136/jmg-2024-109943

Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

Xin Yang, Thea M Mooij, Goska Leslie, Lorenzo Ficorella, Nadine Andrieu, Karin Kast, Christian F Singer, Anna Jakubowska, Carla H van Gils, Yen Y Tan, Christoph Engel, Muriel A Adank, Christi J van Asperen, Margreet G E M Ausems, Pascaline Berthet, Margriet J Collee, Jackie A Cook, Jacqueline Eason, Karin Y van Spaendonck-Zwarts, D Gareth EvansEncarna B Gómez García, Helen Hanson, Louise Izatt, Zoe Kemp, Fiona Lalloo, Christine Lasset, Fabienne Lesueur, Hannah Musgrave, Sophie Nambot, Catherine Noguès, Jan C Oosterwijk, Dominique Stoppa-Lyonnet, Marc Tischkowitz, Vishakha Tripathi, Marijke R Wevers, Emily Zhao, Flora E van Leeuwen, Marjanka K Schmidt, Douglas F Easton, Matti A Rookus, Antonis C Antoniou,

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: No validation has been conducted for the BOADICEA multifactorial breast cancer risk prediction model specifically in BRCA1/2 pathogenic variant (PV) carriers to date. Here, we evaluated the performance of BOADICEA in predicting 5-year breast cancer risks in a prospective cohort of BRCA1/2 PV carriers ascertained through clinical genetic centres. Methods: We evaluated the model calibration and discriminatory ability in the prospective TRANsIBCCS cohort study comprising 1614 BRCA1 and 1365 BRCA2 PV carriers (209 incident cases). Study participants had lifestyle, reproductive, hormonal, anthropometric risk factor information, a polygenic risk score based on 313 SNPs and family history information. Results: The full multifactorial model considering family history together with all other risk factors was well calibrated overall (E/O=1.07, 95% CI: 0.92 to 1.24) and in quintiles of predicted risk. Discrimination was maximised when all risk factors were considered (Harrell's C-index=0.70, 95% CI: 0.67 to 0.74; area under the curve=0.79, 95% CI: 0.76 to 0.82). The model performance was similar when evaluated separately in BRCA1 or BRCA2 PV carriers. The full model identified 5.8%, 12.9% and 24.0% of BRCA1/2 PV carriers with 5-year breast cancer risks of <1.65%, <3% and <5%, respectively, risk thresholds commonly used for different management and risk-reduction options. Conclusion: BOADICEA may be used to aid personalised cancer risk management and decision-making for BRCA1 and BRCA2 PV carriers. It is implemented in the free-access CanRisk tool (https://www.canrisk.org/).

Original language	English
Article number	109943
Pages (from-to)	803-809
Journal	Journal of Medical Genetics
Volume	61
Early online date	4 Jun 2024
DOIs	https://doi.org/10.1136/jmg-2024-109943
Publication status	Published - 19 Jul 2024

Keywords

Early Diagnosis
Genetic Counseling
Public Health
Women's Health

Access to Document

10.1136/jmg-2024-109943Licence: CC BY

803.fullFinal published version, 1.44 MBLicence: CC BY

Cite this

Yang, X., Mooij, T. M., Leslie, G., Ficorella, L., Andrieu, N., Kast, K., Singer, C. F., Jakubowska, A., van Gils, C. H., Tan, Y. Y., Engel, C., Adank, M. A., van Asperen, C. J., Ausems, M. G. E. M., Berthet, P., Collee, M. J., Cook, J. A., Eason, J., Spaendonck-Zwarts, K. Y. V. (2024). Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers. Journal of Medical Genetics, 61, 803-809. Article 109943. https://doi.org/10.1136/jmg-2024-109943

@article{d974fb0b91ee47878535460b0f77aa6b,

title = "Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.",

abstract = "Background: No validation has been conducted for the BOADICEA multifactorial breast cancer risk prediction model specifically in BRCA1/2 pathogenic variant (PV) carriers to date. Here, we evaluated the performance of BOADICEA in predicting 5-year breast cancer risks in a prospective cohort of BRCA1/2 PV carriers ascertained through clinical genetic centres. Methods: We evaluated the model calibration and discriminatory ability in the prospective TRANsIBCCS cohort study comprising 1614 BRCA1 and 1365 BRCA2 PV carriers (209 incident cases). Study participants had lifestyle, reproductive, hormonal, anthropometric risk factor information, a polygenic risk score based on 313 SNPs and family history information. Results: The full multifactorial model considering family history together with all other risk factors was well calibrated overall (E/O=1.07, 95% CI: 0.92 to 1.24) and in quintiles of predicted risk. Discrimination was maximised when all risk factors were considered (Harrell's C-index=0.70, 95% CI: 0.67 to 0.74; area under the curve=0.79, 95% CI: 0.76 to 0.82). The model performance was similar when evaluated separately in BRCA1 or BRCA2 PV carriers. The full model identified 5.8%, 12.9% and 24.0% of BRCA1/2 PV carriers with 5-year breast cancer risks of <1.65%, <3% and <5%, respectively, risk thresholds commonly used for different management and risk-reduction options. Conclusion: BOADICEA may be used to aid personalised cancer risk management and decision-making for BRCA1 and BRCA2 PV carriers. It is implemented in the free-access CanRisk tool (https://www.canrisk.org/).",

keywords = "Early Diagnosis, Genetic Counseling, Public Health, Women's Health",

author = "Xin Yang and Mooij, {Thea M} and Goska Leslie and Lorenzo Ficorella and Nadine Andrieu and Karin Kast and Singer, {Christian F} and Anna Jakubowska and {van Gils}, {Carla H} and Tan, {Yen Y} and Christoph Engel and Adank, {Muriel A} and {van Asperen}, {Christi J} and Ausems, {Margreet G E M} and Pascaline Berthet and Collee, {Margriet J} and Cook, {Jackie A} and Jacqueline Eason and Spaendonck-Zwarts, {Karin Y van} and Evans, {D Gareth} and {G{\'o}mez Garc{\'i}a}, {Encarna B} and Helen Hanson and Louise Izatt and Zoe Kemp and Fiona Lalloo and Christine Lasset and Fabienne Lesueur and Hannah Musgrave and Sophie Nambot and Catherine Nogu{\`e}s and Oosterwijk, {Jan C} and Dominique Stoppa-Lyonnet and Marc Tischkowitz and Vishakha Tripathi and Wevers, {Marijke R} and Emily Zhao and {van Leeuwen}, {Flora E} and Schmidt, {Marjanka K} and Easton, {Douglas F} and Rookus, {Matti A} and Antoniou, {Antonis C}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.",

year = "2024",

month = jul,

day = "19",

doi = "10.1136/jmg-2024-109943",

language = "English",

volume = "61",

pages = "803--809",

journal = "Journal of Medical Genetics",

issn = "0022-2593",

publisher = "BMJ Publishing Group",

}

Yang, X, Mooij, TM, Leslie, G, Ficorella, L, Andrieu, N, Kast, K, Singer, CF, Jakubowska, A, van Gils, CH, Tan, YY, Engel, C, Adank, MA, van Asperen, CJ, Ausems, MGEM, Berthet, P, Collee, MJ, Cook, JA, Eason, J, Spaendonck-Zwarts, KYV, Evans, DG, Gómez García, EB, Hanson, H, Izatt, L, Kemp, Z, Lalloo, F, Lasset, C, Lesueur, F, Musgrave, H, Nambot, S, Noguès, C, Oosterwijk, JC, Stoppa-Lyonnet, D, Tischkowitz, M, Tripathi, V, Wevers, MR, Zhao, E, van Leeuwen, FE, Schmidt, MK, Easton, DF, Rookus, MA, Antoniou, AC 2024, 'Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.', Journal of Medical Genetics, vol. 61, 109943, pp. 803-809. https://doi.org/10.1136/jmg-2024-109943

TY - JOUR

T1 - Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

AU - Yang, Xin

AU - Mooij, Thea M

AU - Leslie, Goska

AU - Ficorella, Lorenzo

AU - Andrieu, Nadine

AU - Kast, Karin

AU - Singer, Christian F

AU - Jakubowska, Anna

AU - van Gils, Carla H

AU - Tan, Yen Y

AU - Engel, Christoph

AU - Adank, Muriel A

AU - van Asperen, Christi J

AU - Ausems, Margreet G E M

AU - Berthet, Pascaline

AU - Collee, Margriet J

AU - Cook, Jackie A

AU - Eason, Jacqueline

AU - Spaendonck-Zwarts, Karin Y van

AU - Evans, D Gareth

AU - Gómez García, Encarna B

AU - Hanson, Helen

AU - Izatt, Louise

AU - Kemp, Zoe

AU - Lalloo, Fiona

AU - Lasset, Christine

AU - Lesueur, Fabienne

AU - Musgrave, Hannah

AU - Nambot, Sophie

AU - Noguès, Catherine

AU - Oosterwijk, Jan C

AU - Stoppa-Lyonnet, Dominique

AU - Tischkowitz, Marc

AU - Tripathi, Vishakha

AU - Wevers, Marijke R

AU - Zhao, Emily

AU - van Leeuwen, Flora E

AU - Schmidt, Marjanka K

AU - Easton, Douglas F

AU - Rookus, Matti A

AU - Antoniou, Antonis C

PY - 2024/7/19

Y1 - 2024/7/19

N2 - Background: No validation has been conducted for the BOADICEA multifactorial breast cancer risk prediction model specifically in BRCA1/2 pathogenic variant (PV) carriers to date. Here, we evaluated the performance of BOADICEA in predicting 5-year breast cancer risks in a prospective cohort of BRCA1/2 PV carriers ascertained through clinical genetic centres. Methods: We evaluated the model calibration and discriminatory ability in the prospective TRANsIBCCS cohort study comprising 1614 BRCA1 and 1365 BRCA2 PV carriers (209 incident cases). Study participants had lifestyle, reproductive, hormonal, anthropometric risk factor information, a polygenic risk score based on 313 SNPs and family history information. Results: The full multifactorial model considering family history together with all other risk factors was well calibrated overall (E/O=1.07, 95% CI: 0.92 to 1.24) and in quintiles of predicted risk. Discrimination was maximised when all risk factors were considered (Harrell's C-index=0.70, 95% CI: 0.67 to 0.74; area under the curve=0.79, 95% CI: 0.76 to 0.82). The model performance was similar when evaluated separately in BRCA1 or BRCA2 PV carriers. The full model identified 5.8%, 12.9% and 24.0% of BRCA1/2 PV carriers with 5-year breast cancer risks of <1.65%, <3% and <5%, respectively, risk thresholds commonly used for different management and risk-reduction options. Conclusion: BOADICEA may be used to aid personalised cancer risk management and decision-making for BRCA1 and BRCA2 PV carriers. It is implemented in the free-access CanRisk tool (https://www.canrisk.org/).

AB - Background: No validation has been conducted for the BOADICEA multifactorial breast cancer risk prediction model specifically in BRCA1/2 pathogenic variant (PV) carriers to date. Here, we evaluated the performance of BOADICEA in predicting 5-year breast cancer risks in a prospective cohort of BRCA1/2 PV carriers ascertained through clinical genetic centres. Methods: We evaluated the model calibration and discriminatory ability in the prospective TRANsIBCCS cohort study comprising 1614 BRCA1 and 1365 BRCA2 PV carriers (209 incident cases). Study participants had lifestyle, reproductive, hormonal, anthropometric risk factor information, a polygenic risk score based on 313 SNPs and family history information. Results: The full multifactorial model considering family history together with all other risk factors was well calibrated overall (E/O=1.07, 95% CI: 0.92 to 1.24) and in quintiles of predicted risk. Discrimination was maximised when all risk factors were considered (Harrell's C-index=0.70, 95% CI: 0.67 to 0.74; area under the curve=0.79, 95% CI: 0.76 to 0.82). The model performance was similar when evaluated separately in BRCA1 or BRCA2 PV carriers. The full model identified 5.8%, 12.9% and 24.0% of BRCA1/2 PV carriers with 5-year breast cancer risks of <1.65%, <3% and <5%, respectively, risk thresholds commonly used for different management and risk-reduction options. Conclusion: BOADICEA may be used to aid personalised cancer risk management and decision-making for BRCA1 and BRCA2 PV carriers. It is implemented in the free-access CanRisk tool (https://www.canrisk.org/).

KW - Early Diagnosis

KW - Genetic Counseling

KW - Public Health

KW - Women's Health

UR - http://www.scopus.com/inward/record.url?scp=85196207999&partnerID=8YFLogxK

U2 - 10.1136/jmg-2024-109943

DO - 10.1136/jmg-2024-109943

M3 - Article

C2 - 38834293

SN - 0022-2593

VL - 61

SP - 803

EP - 809

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

M1 - 109943

ER -

Validation of the BOADICEA model in a prospective cohort of BRCA1/2 pathogenic variant carriers.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this